Herrmann Joerg, Ciechanover Aaron, Lerman Lilach O, Lerman Amir
Division of Cardiovascular Diseases Mayo Clinic, Rochester, MN 55905, USA.
Int J Cardiovasc Intervent. 2005;7(1):5-13. doi: 10.1080/14628840510011234.
The ubiquitin-proteasome system is the two sequential labeling and degradation system that accounts for the degradation of 80-90% of all intracellular proteins. Based on the diversity of its substrates, it is integrated in many different biological processes, especially inflammation and cell proliferation. Given the significance of these two processes for primary atherosclerosis and restenosis, the ubiquitin-proteasome system may be an amendable target in cardiovascular therapy. This review provides background information on the ubiquitin-proteasome system, currently available data on its involvement in cardiovascular diseases, and a future perspective on the targeted use proteasome inhibitors, including drug-eluting stents.
泛素-蛋白酶体系统是一种由两个连续步骤组成的标记和降解系统，负责细胞内80%-90%的蛋白质降解。基于其底物的多样性，该系统参与了许多不同的生物学过程，尤其是炎症和细胞增殖。鉴于这两个过程对原发性动脉粥样硬化和再狭窄的重要性，泛素-蛋白酶体系统可能是心血管治疗中一个可行的靶点。本文综述了泛素-蛋白酶体系统的背景信息、目前关于其参与心血管疾病的现有数据，以及对包括药物洗脱支架在内的蛋白酶体抑制剂靶向应用的未来展望。
